Light-Inducible Protein Aggregation System for Neurodegeneration Modeling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cellular and animal models of proteinopathies, such as Parkinson's disease, do not allow for the monitoring of protein aggregation in living cells and do not form intraneuronal inclusions resembling those found in patients, making it difficult to study the role of protein aggregates in neurodegenerative disorders.
Innovation Solution
A light-inducible intracellular protein aggregation system (LIPA) that uses a cell expressing an alpha-synuclein polypeptide or other proteopathic polypeptide linked to a photoactivatable polypeptide, where illumination triggers the formation of intracellular protein aggregates resembling those found in proteinopathies, enabling spatiotemporal control and real-time monitoring of protein aggregation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cellular and animal models are used, then the models are simple to maintain, but they do not allow monitoring of protein aggregation in living cells and do not form authentic intraneuronal inclusions
Solution Approach 1:
The patent introduces an optogenetic intermediary system where a photoactivatable protein (e.g., CRY2) is fused to the proteopathic polypeptide. Light illumination activates the photoactivatable domain, triggering controlled protein aggregation. This intermediary mechanism enables precise spatiotemporal control of aggregation while maintaining cell viability and allowing real-time monitoring, thus resolving the contradiction between modeling accuracy and system complexity.
2Ease of operation
If protein aggregation is induced without light control, then aggregation occurs spontaneously, but spatiotemporal control and real-time monitoring are not achieved
Solution Approach 1:
The patent replaces spontaneous, uncontrolled biochemical aggregation with an optogenetic control system. Light illumination serves as a non-invasive, precise control mechanism that activates protein aggregation only in specific spatiotemporal windows. This substitution of mechanical/spontaneous processes with optical control achieves ease of operation through simple light activation while enabling real-time monitoring, effectively managing the complexity-tradability balance.
3Loss of information
If aggregation is monitored in living cells, then real-time data is obtained, but the monitoring system becomes more complex and may interfere with natural aggregation processes
Solution Approach 1:
The patent employs fluorescent protein tags (e.g., GFP, mCherry) fused to the proteopathic polypeptide and photoactivatable domain. These fluorescent tags serve multiple functions: they enable real-time visualization of aggregation dynamics, serve as reporters for aggregation status, and do not interfere with the aggregation process itself. This multi-functional approach allows comprehensive monitoring while minimizing additional system complexity, as the same fluorescent components used for activation also enable observation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The LIPA system allows for the rapid and controlled formation of protein aggregates in living cells that resemble those found in proteinopathies, providing a more accurate model for studying neurodegenerative disorders and testing potential treatments.
Implementation Method 1
illumination (light stimulation) of the photoactivatable polypeptide with light having a wavelength sufficient for photoactivation triggers irreversible accumulation of intracellular protein aggregates
Data Source
AI summary
A light-inducible intracellular protein aggregation system is described herein, which provides invaluable tools to study the role of protein aggregates in proteinopathies and to screen for novel therapeutic compounds. The system generally comprises a cell expressing an alpha-synuclein polypeptide or another proteopathic polypeptide that self-aggregates under pathogenic conditions, operably linked to a photoactivatable polypeptide. Illumination of the photoactivatable polypeptide with light having a wavelength sufficient for photoactivation triggers irreversible accumulation of intracellular protein aggregates comprising the alpha-synuclein polypeptide or proteopathic polypeptide. The intracellular protein aggregates can be made to accumulate in real-time during the illumination, thereby enabling spatiotemporal control of protein aggregation. In some embodiments, the intracellular protein aggregates may exhibit pathologically-relevant properties of those found in disease-associated proteinopathies, such as irreversibility, auto-perpetuation (seeding) activity, and comprising misfolded proteins rich in beta-sheet conformation.